Objective: Early initiation of xanthine oxidase inhibitors (XOIs) may benefit patients with preserved kidney function. However, a direct comparison between the impact of allopurinol and those of febuxostat on long-term kidney function among this population is lacking.
Methods: We conducted a retrospective cohort study with a new-user, active-comparator design among patients with eGFR within the reference range and no proteinuria. The primary outcome was a composite incidence of significant eGFR decline (≥ 40% decline from baseline) and all-cause death at 5 years. Adjusted hazard ratios (HRs) were estimated using Cox's proportional hazard models with inverse probability of treatment and censoring weighting.
Results: We analyzed 1,142 patients (287 with allopurinol and 855 with febuxostat). The adjusted HRs (95% confidence intervals) for allopurinol initiators compared to febuxostat initiators for the composite outcome at 5 years were 0.84 (0.74-0.95). The cause-specific adjusted HRs for allopurinol initiators relative to febuxostat initiators were 0.82 (0.70-0.94) for significant eGFR decline over 5 years, and 1.08 (0.91-1.24) for all-cause death over 5 years.
Conclusion: Allopurinol initiators preserved kidney function better than febuxostat over 5 years. Clinicians should exercise caution not only when prescribing but also when selecting XOIs, even for patients with preserved kidney function.
Keywords: allopurinol; febuxostat; glomerular filtration rate; gout; hyperuricemia.
© Japan College of Rheumatology 2024. Published by Oxford University Press. All rights reserved. For commercial re-use, please contact [email protected] for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site–for further information please contact [email protected].